Last reviewed · How we verify
Experimental Peritoneal Dialysis Solution
An experimental peritoneal dialysis solution designed to improve solute clearance and fluid removal in patients with end-stage renal disease undergoing peritoneal dialysis.
An experimental peritoneal dialysis solution designed to improve solute clearance and fluid removal in patients with end-stage renal disease undergoing peritoneal dialysis. Used for End-stage renal disease requiring peritoneal dialysis.
At a glance
| Generic name | Experimental Peritoneal Dialysis Solution |
|---|---|
| Sponsor | Vantive Health LLC |
| Drug class | Peritoneal dialysis solution |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | Phase 3 |
Mechanism of action
Peritoneal dialysis solutions facilitate the removal of uremic waste products and excess fluid across the peritoneal membrane. This experimental formulation likely incorporates novel osmotic agents, electrolyte compositions, or biocompatible additives to enhance dialysate performance and reduce peritoneal membrane injury compared to conventional solutions.
Approved indications
- End-stage renal disease requiring peritoneal dialysis
Common side effects
- Peritonitis
- Hyperglycemia (if glucose-based)
- Electrolyte imbalances
- Abdominal discomfort
Key clinical trials
- Efficacy and Safety of XyloCore Peritoneal Dialysis Solution. (PHASE3)
- Clinical Study of the Use of Amino Acid Peritoneal Dialysate in Diabetic Patients (NA)
- A Study to Evaluate the Efficacy and Safety of an Experimental Solution for Peritoneal Dialysis (PHASE3)
- A Subjective Evaluation of Inflow Pain Associated With the Use of an Experimental Solution for Peritoneal Dialysis (NA)
- Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition. (PHASE4)
- Effect of Agave Inulin on Constipation and Quality of Life in Peritoneal Dialysis Patients. (NA)
- Incremental PD With Single Icodextrin Exchange (NA)
- Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol, and L-Carnitine in CAPD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: